| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25037 |
| Drug |
Glofitamab |
| Brand |
Columvi® |
| Indication |
Glofitamab in combination with gemcitabine and oxaliplatin is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are ineligible for autologous stem cell transplant (ASCT). |
| Rapid review commissioned |
30/05/2025 |
| Rapid review completed |
02/07/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of glofitamab in combination with gemcitabine and oxaliplatin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
30/07/2025 |
| Pre-submission consultation with Applicant |
24/09/2025 |
